Pfizer Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (364)

Latest Posts

About This Stock More About This Stock
18 Drugs To Lose Patents In 2017; Could Jeopardize $26.5B For Big Pharma
Article By: Lorimer Wilson
Saturday, April 22, 2017 8:24 PM EDT
With 18 branded drugs on the line, patent losses this year could jeopardize $26.5 billion in annual sales from Big Pharma, projected to be the biggest fall-off until at least 2025.
In this article: AZN, BMY, GSK, LLY, MRK, PFE, SNY, RHHBY, TEVA
Read
Week In Review: Tianjin CanSino Closes $65 Million Round For Vaccine Portfolio
Article By: ChinaBio® Today
Saturday, April 22, 2017 3:40 PM EDT
Tianjin CanSino Biologics, a vaccine developer, raised $65 Million in its latest funding round. Currently, CanSino is testing four products in Phase I to III clinical trials, conducted in North America, Africa and China respectively.
In this article: MRK, PFE, CELG, IONS, BGNE
Read
Samsung Bioepis' Knockoff Latest Competition For Johnson & Johnson's Blockbuster, Remicade
Article By: Lorimer Wilson
Friday, April 21, 2017 8:34 PM EDT
JNJ’s Remicade earned close to $7 billion last year, making it by far the biggest drug in their portfolio but the FDA has approved a new knockoff which may finally start to shift the market dynamics toward greater competition with lower prices.
In this article: JNJ, MRK, NVS, PFE, BIIB
Read
Better Big Pharma Dividend Stock: Pfizer Or Teva?
Article By: SureDividend
Wednesday, April 19, 2017 11:44 AM EDT
Teva has a very low valuation, and a solid dividend yield. Pfizer has a more secure dividend. And, its dividend is not subject to any withholding tax.
In this article: PFE, TEVA Also: VRX, JNJ
Read
Pharma Stock Roundup: Merck Gets CRL For Label Expansion Effort, Roche Cancer Drug Tops
Article By: Arpita Dutt
Friday, April 14, 2017 12:00 PM EDT
It was a relatively slow week with key highlights including a complete response letter (CRL) for Merck’s label expansion efforts for its diabetes drugs and positive data on Roche’s lung cancer treatment.
In this article: AZN, JNJ, MRK, MYL, RHHBY, PFE, BMY
Read

PARTNER HEADLINES

Latest Tweets for $PFE

No tweets yet!